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Abstract  20 
Smoking is a significant risk factor for the development of metabolic diseases. Due to social 21 
pressures to quit smoking, many pregnant women are vaping as an alternative nicotine source. 22 
However, the metabolic consequences of replacing tobacco cigarettes with e-cigarettes during 23 
pregnancy are unknown. Therefore, in the mothers and their offspring, we investigated the 24 
metabolic and hepatic impacts of replacing cigarette smoke with e-vapour during pregnancy.  25 
Female BALB/c mice were either air-exposed or cigarette smoke-exposed (SE) from six weeks 26 
before pregnancy until lactation. At mating, a subset of the SE mice were instead exposed to 27 
e-vapour. Markers of glucose and lipid metabolism were measured in the livers and plasma, 28 
from the mothers and their male offspring (13 weeks).  In the SE mothers, plasma insulin levels 29 
were reduced, leading to downstream increases in hepatic gluconeogenesis and plasma non-30 
esterified fatty acids (NEFA). In the e-vapour replacement mothers, these changes were not as 31 
significant. In the SE offspring, there was impaired glucose tolerance, and increased plasma 32 
NEFA and liver triglyceride concentrations. E-vapour replacement restored lipid homeostasis 33 
but did not improve glucose tolerance. Therefore, e-cigarette replacement during pregnancy in 34 
a low dose setting seems to ameliorate the adverse impact of cigarette smoke exposure on 35 
maternal and offspring liver metabolic profile in mice; while future research needs to focus on 36 
higher doses to verify such effects.  37 




ATGL  Adipose triglyceride lipase 40 
AUC   Area under the curve 41 
CPT1a  Carnitine palmitoyltransferase Ia 42 
FASN   Fatty acid synthase 43 
FOXO1  Forkhead box protein O1 44 
GLUT  Glucose transporter 45 
IPGTT  Intraperitoneal glucose tolerance test  46 
NEFA  Non-esterified fatty acid 47 
PFK   Phosphofructokinase 48 
PGC-1α Peroxisome proliferator-activated receptor gamma coactivator 1-alpha 49 
PPAR-γ  Peroxisome proliferator-activated receptor gamma 50 
SEM  Standard error of the mean   51 
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1. Introduction 52 
Type 2 diabetes is a primary global health concern, affecting approximately 400 million 53 
individuals worldwide and contributing to 3.7 million deaths each year 1. Smoking is a 54 
significant risk factor, estimated to increase the risk of Type 2 diabetes by 30-40% 2. 55 
Furthermore, smoking during pregnancy restricts intrauterine resources and primes the foetus 56 
to develop insulin resistance 3 and hepatic steatosis 4 later in life. Thus, smoking cessation 57 
during pregnancy will optimise the health outcome of the next generation 5. However, smoking 58 
cessation can be difficult to achieve, especially since nicotine replacement therapy is mostly 59 
ineffective during pregnancy 6. 60 
Driven by health advice to quit smoking, many pregnant smokers switch to e-cigarettes upon 61 
learning of their pregnancy 7, especially since vaping is less stigmatised than smoking 8. E-62 
cigarettes are marketed as a smoking cessation aid, supposedly delivering inhaled nicotine 63 
without the harmful by-products of tobacco combustion 4. The popularisation of replacement 64 
vaping is mostly derived from safety perceptions compared to smoking, among pregnant 65 
women 8,9 and even some obstetricians 10. During pregnancy, ever use of e-cigarettes ranges 66 
from 13% to 15% 11,12, making them more prevalent than other forms of nicotine replacement 67 
therapy 8,13.  68 
While it is clear that vaping is not safe 14, switching from smoking to vaping may be beneficial 69 
among long-term smokers 15. However, there are no reports on the impacts of switching during 70 
pregnancy, due to the recent emergence of e-cigarettes on the market. In mouse models, we 71 
have previously shown that intrauterine e-vapour exposure during pregnancy altered 72 
inflammatory responses in multiple organs (lungs 16, brain 17,18 and kidneys 19). Furthermore, 73 
replacing tobacco cigarettes with e-cigarettes during pregnancy was less harmful to the brains 74 
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and kidneys compared to continuous cigarette smoke exposure throughout gestation and 75 
lactation 18-20.  76 
The increased risk of type 2 diabetes due to in-utero cigarette smoke exposure makes it 77 
essential to investigate the metabolic impacts of e-cigarette replacement during pregnancy. The 78 
liver is a major metabolic hub, contributing to systemic glucose and lipid homeostasis which 79 
becomes dysregulated in metabolic diseases, such as type 2 diabetes 21. Using a Balb/c mouse 80 
model, we aimed to investigate the impacts of replacing cigarette smoke with e-cigarette 81 
vapour during pregnancy on systemic and hepatic metabolic profiles in both the mothers and 82 
their offspring.  83 
2. Methods 84 
2.1. Animals 85 
The animal experiments were approved by the Animal Care and Ethics Committee of the 86 
University of Technology Sydney (ACEC2014-638 and ETH15-0025) and performed 87 
according to the Australian National Health & Medical Research Council Guide for the Care 88 
and Use of Laboratory Animals. Virgin female BALB/c mice (7 weeks old, Animal Resource 89 
Centre, WA, Australia) had ad libitum access to standard laboratory chow and water while 90 
housed at 20±2 °C and maintained on a 12-h light, 12-h dark cycle (lights on at 06:00 h). 91 
Female breeders were acclimatised for a week prior to the exposure treatments detailed below.  92 
Female breeders were either room air exposed (Sham group, n=8) or cigarette smoke exposed 93 
(SE group, n=16) to 2 cigarettes (Winfield Red, ≤16 mg tar, ≤1.2 mg nicotine, and ≤15 mg of 94 
CO; VIC, Australia) twice daily, 6 weeks before mating and throughout gestation and lactation. 95 
In a subset of the SE mice, cigarette smoke was replaced with e-vapour generated from 96 
commercial e-liquid (50% propylene glycol/50% vegetable glycerine, tobacco flavour, Vaper 97 
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Empire, VIC, Australia) containing 18mg/mL nicotine (Replacement group, n=8) from mating 98 
until the pups were weaned, as previously described 16. Aerosols were generated by a human-99 
use e-cigarette (KangerTech NEBOX, 30 Watts, 0.5 Ohms, KangerTech, Shenzen, China) as 100 
we have previously published in the same model 16. Offspring plasma cotinine (a major, stable 101 
nicotine metabolite) concentrations were measured in previous studies 16,22 and were similar in 102 
the SE and Replacement groups. This nicotine dose represents mothers who are light smokers 103 
23.  104 
Dams were removed from their home cages and whole-body exposed to cigarette smoke or e-105 
cigarette vapour. Sham dams were placed in identical exposure chambers without any smoke 106 
or vapour. Male breeders and pups were not exposed. Male offspring were weaned at postnatal 107 
day 20 and maintained without additional intervention. At 12 weeks of age, an intraperitoneal 108 
glucose tolerance test (IPGTT) was performed as previously described 24. After 5 hours of 109 
fasting, baseline blood glucose levels were measured followed by glucose injection (2g/kg, IP). 110 
Blood glucose was measured at 15, 30, 60, and 90 minutes post-injection. The area under the 111 
curve (AUC) of the blood glucose curve was calculated for each mouse. We euthanised dams 112 
(at weaning) and male offspring (at 13 weeks old) after deep anaesthesia (2% isoflurane).  113 
Livers were harvested, weighed and then either snap frozen and stored at -80°C, or fixed in 114 
10% formalin for further analyses. Liver weights (%) were calculated as a fraction of body 115 
weight. Blood was collected via cardiac puncture, and glucose levels were measured (Accu-116 
Chek(R), Roche, CA, USA). Plasma was separated and stored at -20°C for further analysis.  117 
In the offspring, the average body and liver weight data of each litter was calculated before 118 
statistical analysis. One male offspring from each litter (n=8) was used for all further 119 
experiments.  120 
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2.2. Bioassays  121 
Plasma insulin concentration was measured using an Insulin (mouse) ELISA Kit (Abnova, 122 
Taiwan) according to the manufacturer’s instructions. Samples were analysed in duplicate, and 123 
the intra-assay coefficient of variance was below 10%.  124 
Liver lipids were extracted using the Folch method 26, as previously described 24. Plasma, liver 125 
extracts and glycerol standards (Sigma-Aldrich, MO, USA) were incubated with 126 
triacylglycerol reagent (Roche Diagnostics, Basel, Switzerland) using an in-house assay 24. 127 
Plasma nonesterified free fatty acid (NEFA) concentrations were measured using a NEFA kit 128 
(WAKO, Osaka, Japan).  129 
2.3. rt-PCR 130 
Total mRNA was extracted from frozen liver tissue with TriZol reagent (Life Technologies, 131 
CA, USA) and first strand cDNA was generated using M-MLV Reverse Transcriptase, RNase 132 
H, Point Mutant Kit (Promega, WI, USA). Target gene expression was quantified with 133 
manufacturer pre-optimised and validated TaqMan primers and probes (Table 1, Thermo 134 
Fisher, CA, USA) and standardised to 18s RNA. The probes of the target genes were labelled 135 
with FAM and those for housekeeping 18s RNA were labelled with VIC. The average of the 136 
Sham group was assigned the calibrator against which all other results were expressed as fold 137 
changes. 138 
2.4. Statistical Analysis 139 
Results are expressed as mean ± standard error of the mean (SEM) and were analysed using 140 
one-way ANOVA with Fisher’s Least Significant post hoc test if the data were normally 141 
distributed. If the data were not normally distributed, they were log transformed to achieve 142 
normality of distribution before analysis (GraphPad Prism 7.03, CA, USA). P<0.05 was 143 
considered the threshold for statistical significance. 144 
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Table 1. TaqMan Probe sequence (Life Technologies, CA, USA) used for rt-PCR. 145 
Gene NCBI references Probe Sequence ID 
ATGL NM_025802.3 CCAAGACTGAATGGCTGGATGGCAA Mm00503040_m1 
CPT1a NM_013495.2  TTCCAGGAGAATGCCAGGAGGTCAT Mm01231183_m1 
FASN NM_007988.3 AGCAATTGTGGATGGAGGTATCAAC Mm00662319_m1 
FOXO1 NM_019739.3 TCGGCGGGCTGGAAGAATTCAATTC Mm00490671_m1 
GLUT2 NM_031197.2 CCGCCTCCCCCGGCGCGCACACACC Mm00446229_m1 
GLUT4 NM_009204.2 TGGCTCTGCTGCTGCTGGAACGGGT Mm00436615_m1 
PFK NM_008826.4 GCGGTGATGCGCAAGGTATGAATGC Mm00435587_m1 
PGC1a NR_027710.1 CTGGAACTGCAGGCCTAACTCCTCC Mm01208835_m1 
PPAR-γ NM_0011273330.1 ATGCTGTTATGGGTGAAACTCTGG Mm01184322_m1 
ATGL: Adipose triglyceride lipase, CPT1a: Carnitine palmitoyltransferase 1a, FASN: Fatty 146 
acid synthase, FOXO1: Forkhead box protein O1, GLUT2: Glucose transporter 2, GLUT4: 147 
Glucose transporter 4, PFK: phosphofructokinase, PGC1a:  Peroxisome proliferator-activated 148 
receptor gamma coactivator 1-α, PPAR-γ: Peroxisome proliferator-activated receptor gamma.  149 
3. Results  150 
3.1. Dams 151 
After continuous exposure to tobacco cigarette smoke, smoke exposed (SE) dams had lower 152 
body weights (P<0.05 vs Sham, Table 2). Liver weights expressed as a percentage of body 153 
weight were higher in the SE dams (P<0.05 vs Sham, Table 2). When the cigarette smoke was 154 
replaced by nicotine-containing e-vapour (Replacement), the reduction in body weight was 155 
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partially prevented, but liver weight remained higher when expressed as a percentage of body 156 
weight (P<0.05 vs Sham, Table 2).  157 
Plasma glucose levels were not different among the groups (Table 2). However, plasma insulin 158 
levels in the SE dams were decreased compared to the Sham dams (P<0.05, Table 2). There 159 
was an increase in the hepatic expression of glucose metabolic markers in the SE dams, 160 
including Glucose Transporter (Glut)4 (P<0.05 vs Sham, Figure 1b), Peroxisome Proliferator-161 
Activated Receptor (PPAR)-γ (P<0.01 vs Sham, Figure 1d), PPARG coactivator (PGC)-1α 162 
(P<0.01 vs Sham, Figure 1e) and Forkhead box protein O1 (FOXO1, P<0.05 vs Sham, Figure 163 
1f). Plasma insulin levels were reversed in the Replacement dams compared to the SE dams 164 
(P<0.01, Table 2). While the expression of Glut4 was increased in the Replacement dams 165 
compared to the Sham dams (P<0.05, Figure 1b), the expression of other glucose metabolic 166 
markers (PPAR-γ, PGC-1α, and FOXO1) were nearly restored to Sham levels. 167 
While there were no differences in plasma triglyceride levels, plasma non-esterified fatty acid 168 
(NEFA) concentration was increased in the SE dams (P<0.05 vs Sham, Table 2). Liver 169 
triglyceride concentration and lipid metabolic markers, fatty acid synthase (FASN), adipose 170 
triglyceride lipase (ATGL) and carnitine palmitoyltransferase 1A (CPT1a) were not 171 
significantly changed in the SE dams (Table 2, Figure 1g-i). Plasma NEFA levels in the 172 
Replacement dams were nearly restored to Sham levels (Table 2), and liver ATGL expression 173 
in the Replacement dams was increased compared to the SE dams (P<0.01, Figure 1h). 174 
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Table 2. Parameters of the dams.  175 
 Sham SE P 
(vs Sham) 




Body weight (g) 26.1±0.38 23.1±0.84 P<0.05 24.9±0.51 NS NS 
Liver weight (g) 1.55 ± 0.07 1.53±0.06 NS 1.68±0.11 NS NS 
Liver weight (%) 5.93±0.22 6.62±0.13 P<0.05 6.74±0.32 P<0.05 NS 
Blood glucose (mM) 9.42 ± 0.83 8.43 ±0.70 NS 9.98±0.43 NS NS 
Plasma insulin (ng/mL) 0.70 ±0.05 0.50 ± 0.01 P<0.05 0.88 ± 0.11 NS P<0.01 
Liver triglyceride (mg/g liver) 4.0±0.57 4.1±0.71 NS 3.7±0.34 NS NS 
Plasma triglyceride (mg/mL) 1.22±0.21 1.01±0.26 NS 0.93±0.21 NS NS 
Plasma NEFA (mEq/L) 2.1 ± 0.28 3.65 ± 0.32 P<0.05 2.91 ± 0.23 NS NS 
Results are expressed as Mean ± SEM, n=8. Data were analysed by one-way ANOVA with Fishers LSD post hoc tests. *P<0.05 vs Sham, ##P<0.01 176 













































































































































































































































































Figure 1. Hepatic mRNA expression of glucose metabolic markers (Glut2 (a), Glut4 (b), PFK1 180 
(c), PPAR-γ (d), PGC-1α (e), FOXO1 (f)) and lipid metabolic markers (FASN (g), ATGL (h), 181 
CPT1a (i)) in the dams. Results are expressed as Mean ± SEM, n=6. Data were analysed by 182 
one-way ANOVA with Fishers LSD post hoc tests. *P<0.05, **P<0.01 vs Sham, ##P<0.01 vs 183 
SE. Glut: glucose transporter; PFK: Phosphofructokinase; PPAR-γ: Peroxisome proliferator-184 
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activated receptor gamma; Peroxisome proliferator-activated receptor gamma coactivator 1-185 
alpha; FOXO1: Forkhead box protein O1; FASN: Fatty acid synthase; ATGL: Adipose 186 
triglyceride lipase; CPT1a: Carnitine palmitoyltransferase I; SE: cigarette smoke exposure; 187 
Replacement: e-vapour replacing SE during gestation. 188 
3.2. Male offspring (13 weeks old) 189 
Adult SE offspring had lower body weights and liver weights (P<0.01 vs Sham, Table 3). In 190 
contrast, the Replacement offspring had no changes in body (P<0.01 vs SE, Table 3) and liver 191 
weights (P<0.05 vs SE, Table 3). 192 
The AUC for the IPGTT was increased in the SE offspring (P<0.05 vs Sham, Table 3), which 193 
is consistent with our previous studies 20,27. However, there were no changes in fasting blood 194 
glucose or plasma insulin levels in the SE offspring. Furthermore, there were no changes in the 195 
mRNA expression of glucose metabolic markers, including Glut2, Glut4, PFK, PPAR-γ, PGC-196 
1α (P=0.056), and FOXO1 compared to the Sham offspring (Figure 2a-f). Glucose metabolism 197 
was impaired (increased AUC of the IPGTT) in the Replacement offspring (P<0.01 vs Sham, 198 
P=0.071 vs SE, Table 3). No changes were found in fasting blood glucose and plasma insulin 199 
levels. The gluconeogenesis regulator, FOXO1, was significantly increased compared to the 200 
Sham and SE offspring (both P<0.05, Table 3, Figure 2f). 201 
Liver triglyceride concentrations were increased in the SE offspring (P<0.05 vs Sham, Table 202 
3), without any changes in plasma triglyceride concentrations. However, plasma NEFA 203 
concentrations were increased in the SE offspring (P<0.01 vs Sham, Table 3). SE offspring 204 
exhibited no changes in the mRNA expression of hepatic lipid metabolic markers, including 205 
FASN, ATGL, and CPT1a compared to the Sham offspring (Figure 2g-i). Increased liver 206 
triglyceride and plasma NEFA concentrations in the SE offspring were not observed in the 207 
Replacement offspring (P<0.01 vs SE, Table 3). In the Replacement offspring, mRNA 208 
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expression of FASN was similar to the Sham offspring level (P<0.05 vs SE offspring, Figure 209 
2g). Replacement offspring had increased hepatic expression of ATGL (P<0.01, Figure 2h) and 210 
CPT1a (P<0.05, Figure 2i) compared to both Sham and SE offspring.211 
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Table 3. Parameters of the offspring  212 








Body weight (g) 26.4±0.61 24.42±0.29 P<0.01 25.92±0.29 NS P<0.01 
Liver weight (g) 1.34±0.06 1.077±0.02 P<0.01 1.23±0.03 NS P<0.05 
Liver weight (%) 5.06±0.16 4.40±0.09 P<0.01 4.75±0.11 NS P<0.05 
IPGTT AUC (mM•min) 1146±20 1281±41 P<0.05 1435±69 P<0.01 NS 
Blood glucose (mM) 12.58±0.45 11.12±0.44 NS 11.92±0.57 NS NS 
Plasma insulin (ng/mL) 0.50±0.015 0.51±0.016 NS 0.51±0.017 NS NS 
Liver triglyceride (mg/g liver) 3.92±0.45 5.26±0.39 P<0.05 3.65±0.50 NS P<0.01 
Plasma triglyceride (mg/mL) 1.41±0.11 1.52±0.25 NS 1.31±0.09 NS NS 
Plasma NEFA (mEq/L) 4.13±0.47 7.6±0.88 P<0.01 4.42±0.45 NS P<0.01 
Results are expressed as Mean ± SEM, n=8. Data were analysed by one-way ANOVA with Fishers LSD post hoc tests. *P<0.05, **P<0.01 vs 213 
Sham, #P<0.05, ##P<0.01 vs Replacement. AUC: area under the curve; IPGTT: intraperitoneal glucose tolerance test; NEFA: non-esterified fatty 214 









































































































































































































































































Figure 2. Hepatic mRNA expression of glucose metabolic markers (Glut2 (a), Glut4 (b), PFK1 217 
(c), PPAR-γ (d), PGC-1α (e), FOXO1 (f)) and lipid metabolic markers (FASN (g), ATGL (h), 218 
CPT1a (i)) in the male offspring at 13 weeks. Results are expressed as Mean ± SEM, n=6. Data 219 
were analysed by one-way ANOVA with Fishers LSD post hoc tests. *P<0.05, **P<0.01 vs 220 
Sham, #P<0.05, ##P<0.01 vs SE. Glut: glucose transporter; PFK: Phosphofructokinase; PPAR-221 
γ: Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated 222 
receptor gamma coactivator 1-alpha; FOXO1: Forkhead box protein O1; FASN: Fatty acid 223 
16 
 
synthase; ATGL: Adipose triglyceride lipase; CPT1a: Carnitine palmitoyltransferase I; SE: 224 
cigarette smoke exposure; Replacement: e-vapour replacing SE during gestation 225 
4. Discussion 226 
E-cigarettes are marketed to smokers as a cessation aid or alternative nicotine source. As a 227 
result, many smokers switch to vaping during pregnancy due to the stigmatisation of smoking 228 
during pregnancy 8, even though the impacts on glucose and lipid metabolism are unknown. In 229 
this study, we found that cigarette smoke exposure during pregnancy affects circulating insulin 230 
and NEFA levels in the dams and caused glucose intolerance and increased circulating NEFA 231 
levels and liver triglyceride concentrations in the offspring. Meanwhile, switching to vaping 232 
during pregnancy seems to benefit the dams but did not improve glucose intolerance in the 233 
offspring.  234 
Here, we confirm the negative impacts of cigarette smoke exposure on glucose and lipid 235 
metabolism in the dams, which mostly did not occur in the e-vapour replacement group. Direct 236 
exposure to cigarette smoke resulted in a decrease in plasma insulin concentrations, consistent 237 
with the adverse impact of smoking on β-cell function 28. Reduced insulin signalling usually 238 
increases PGC-1α, which promotes hepatic gluconeogenesis through the activation of the 239 
transcription factor FOXO1 29. In addition, reduced insulin signalling can increase lipolysis in 240 
adipose tissue, resulting in elevated plasma NEFA concentrations 30, which we observed in the 241 
SE dams. Therefore, direct exposure to tobacco cigarette smoke can result in insulin deficiency, 242 
leading to downstream increases in gluconeogenesis and lipolysis, causing plasma NEFA to 243 
increase.  244 
However, when tobacco cigarette smoke was replaced by e-vapour, plasma insulin 245 
concentrations were restored, with normalised hepatic gluconeogenesis and plasma NEFA 246 
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concentrations. In human smokers, e-cigarette replacement has been shown to improve their 247 
lung function, oral health and cardiovascular outcomes  15,31. Therefore, replacing e-cigarettes 248 
with tobacco cigarettes may benefit the regulation of hepatic glucose and lipid metabolism in 249 
the direct user.  250 
Previously, we found that replacing cigarette smoke with nicotine-containing e-vapour during 251 
pregnancy can normalise brain metabolic regulators in the offspring 18. However, the metabolic 252 
impacts in the offspring are unknown. Intrauterine exposure to cigarette smoke impaired 253 
glucose tolerance in adult offspring, which is consistent with our previous studies and effects 254 
in humans 27,32. Increased liver triglyceride concentration and plasma NEFA concentrations 255 
were also increased in the SE offspring, which is commonly associated with low birth weight 256 
33, a major effect of maternal smoking 4. However, only the main metabolic regulator PGC1α 257 
was reduced in the SE offspring, which may account for glucose intolerance, increased plasma 258 
NEFA and liver triglyceride accumulation. Although plasma insulin concentration and liver 259 
gluconeogenesis marker, FOXO1, were not changed, we cannot rule out the possibility of 260 
impaired insulin release in response to a postprandial glucose surge.  261 
Meanwhile, in the Replacement offspring, hepatic triglyceride and plasma NEFA 262 
concentrations were restored to normal levels. This was likely due to decreased de-novo 263 
lipogenesis (normalised FASN expression) and increased lipolysis and fatty acid β-oxidation 264 
(increased ATGL and CPT-1α expression) within the liver. However, glucose intolerance was 265 
not improved in the Replacement offspring. Thus, replacing tobacco cigarettes with e-cigarettes 266 
during pregnancy restored hepatic lipid metabolism, but did not reduce the risk of type 2 267 
diabetes in the offspring. E-cigarette vapour contains toxins in lower quantities than cigarette 268 
smoke, likely leading to reduced inflammatory responses 34. Therefore, it is not surprising that 269 
e-cigarette replacement during pregnancy was not as detrimental as tobacco cigarette smoke.  270 
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This is the first study to report the metabolic consequences of intrauterine e-vapour exposure, 271 
but there are some limitations. Since only male offspring were used in this study, the impacts 272 
on female offspring are unknown. We also used a whole-body exposure protocol which may 273 
result in oral exposure through grooming. Although we report differences in mRNA expression 274 
in this study, the impact at the protein level is unknown and should be investigated in future 275 
studies. This study used a low exposure regime (nicotine exposure equivalent to light smokers), 276 
and future studies should investigate the impact of higher doses of both cigarette smoke and e-277 
vapour. Furthermore, this study did not examine the impacts of complete smoking cessation 278 
during pregnancy, which may provide an additional benefit compared to e-cigarette 279 
replacement.  280 
In conclusion, replacing tobacco cigarette smoke with e-vapour benefited maternal metabolic 281 
outcomes. In the offspring, e-cigarette replacement improved lipid metabolism but not glucose 282 
homeostasis. Therefore, e-cigarettes may be an alternative nicotine source among pregnant 283 
women who are unable to quit smoking by other means. However, e-cigarette vaping still has 284 
other health risks, which was highlighted by the recent vaping associated deaths in the US 14. 285 
Furthermore, other issues must also be considered regarding vaping, including dual-use and 286 
youth uptake 35.  287 
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